Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 7/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.34 |
| ▸ | AKT1 | P31749 | 3/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.34 |
| ▸ | IDE | P14735 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776231 | 0.84 | AKT1 (0.40) | AKT1GRM4AKT2AKT3P2RY12 | |
| SCHEMBL1774986 | 0.83 | GRIA1 (0.41) | AKT1AKT2AKT3 | |
| SCHEMBL1776952 | 0.72 | P2RY12 (0.41) | AKT1AKT2AKT3P2RY12 | |
| SCHEMBL1776820 | 0.72 | MEN1 (0.47) | — | |
| SCHEMBL1775701 | 0.72 | TRPV1 (0.40) | TRPA1TRPV1 | |
| SCHEMBL1775123 | 0.72 | ALDH1A1 (0.42) | AKT1AKT2AKT3P2RY12 | |
| SCHEMBL1776477 | 0.71 | AKT1 (0.40) | TRPA1TRPV1AKT1AKT2AKT3 | |
| SCHEMBL1775510 | 0.71 | ACHE (0.48) | — | |
| SCHEMBL1776052 | 0.71 | TRPA1 (0.41) | TRPA1TRPV1IDE | |
| SCHEMBL1774709 | 0.70 | TRPA1 (0.42) | TRPA1TRPV1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |